Bluejay Diagnostics, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Bluejay Diagnostics entered a 2-year distribution and co-marketing agreement (effective Sept 1, 2026) with Lovell Government Services, a Service-Disabled Veteran-Owned Small Business. Lovell gains exclusive rights to distribute Bluejay's products through federal set-aside procurement (VA, DoD, IHS) and non-exclusive rights for open-market federal/state/local sales. Bluejay pays a one-time $5,500 establishment fee (discounted from $25,000) and a 15% gross sales distribution fee on federal catalog sales; Lovell covers government contract fees. The agreement positions Bluejay to access the VA ($165.1B budget), DoD ($64B), and IHS ($8.1B) healthcare systems pending FDA clearance of its Symphony diagnostic platform.
Why this rating
Material pre-commercialization step for $2.6M market-cap company. Establishes distribution infrastructure before FDA approval; targets multi-hundred-billion federal healthcare opportunity. Deal structure (15% fee, modest upfront cost) is reasonable. Contingent on regulatory clearance; no guaranteed sales. Significant relative to company size but execution risk remains high.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.02 ▼ 0.97% | at our read · unknown $1.03 | +10 min · unknown $1.03 ▲ 0.00% | +30 min · unknown $1.03 ▲ 0.00% | +1 hr · unknown $1.03 ▲ 0.00% | +4 hrs pending |
The stock had already moved +0.98% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.